ORAMED PHARMACEUTICALS INC.
For the period ended Dec 31, 2024. Filed Mar 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 27, 2025
ORMP$3.97-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
In thousands
| Year ended December 31, | Year ended December 31, | |
|---|---|---|
| 2024 | 2023 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net income (loss) | $(19,103) | $5,088 |
| Adjustments required to reconcile net income (loss) to net cash used in operating activities: | ||
| Depreciation | 193 | 196 |
| Exchange differences, accrued interest on deposits and held to maturity bonds | (2,700) | (2,172) |
| Changes in fair value of investments | 7,413 | (16,392) |
| Stock-based compensation | 4,053 | 4,212 |
| Shares issued for services | - | 9 |
| Funds in respect of employee rights upon retirement | (5) | (3) |
| Change in accrued interest on short-term borrowings to maturity | (1,463) | 1,463 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (356) | 852 |
| Accounts payable, accrued expenses and related parties | 3,525 | (2,225) |
| Net changes in operating lease | 43 | 8 |
| Deferred revenues | - | (1,340) |
| Liability for employee rights upon retirement | 2 | 7 |
| Other liabilities | (14) | 2 |
| Total net cash used in operating activities | (8,412) | (10,295) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchase of property and equipment | (18) | (254) |
| Purchase of short-term deposits | (54,450) | (91,369) |
| Proceeds from redemption of short-term deposits | 97,152 | 109,760 |
| Exercise of Closing Penny Warrants and Subsequent Penny Warrants | (65) | - |
| Long-term investments | (1,307) | (99,550) |
| Proceeds from long-term deposits | 5 | - |
| Proceeds from long-term investments | 64,500 | 5,000 |
| Proceeds from maturity of held to maturity securities | - | 3,375 |
| Total net cash provided by (used in) investing activities | 105,817 | (73,038) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from issuance of common stock, net of issuance costs | - | 2,428 |
| Repurchase and retirement of common stock | (2,484) | - |
| Loans received | - | 99,550 |
| Loans repaid | (49,550) | (50,000) |
| Tax withholdings related to stock-based compensation settlements | (2) | - |
| Total net cash provided by (used in) financing activities | (52,036) | 51,978 |
| EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS | (4) | (54) |
| INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | 45,365 | (31,409) |
| CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR | 9,055 | 40,464 |
| CASH AND CASH EQUIVALENTS AT END OF YEAR | $54,420 | $9,055 |
| (A) SUPPLEMENTARY DISCLOSURE ON CASH FLOWS: | ||
| Interest paid | $2,316 | $574 |
| Interest received | $7,376 | $5,156 |
| (B) SUPPLEMENTAL DISCLOSURE OF NON-CASH ACTIVITIES: | ||
| 2024 Refinancing Tranche A | (21,575) | - |
| 2024 Refinancing Tranche B | 25,000 | - |
| Excise tax for repurchase and retirement of common stock | (10) | - |
| Recognition of operating lease right-of-use assets and liabilities | 58 | - |
| Derecognition of right-of-use asset | (26) | - |
| Derecognition of lease liability | 23 | - |
The accompanying notes are an integral part of the consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.